Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia

Autor: Sebnem Pirildar, Meral Kayıkçıoğlu, Levent Can, Lale Tokgozoglu, Özlem Kuman Tunçel
Jazyk: angličtina
Rok vydání: 2021
Předmět:
2019-20 coronavirus outbreak
Letter
Coronavirus disease 2019 (COVID-19)
Endocrinology
Diabetes and Metabolism
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
social media
Lipoproteins
apheresis
Familial hypercholesterolemia
patient compliance
Article
low density lipoprotein cholesterol
Hyperlipoproteinemia Type II
coronavirus disease 2019
lipoprotein apheresis
health care access
healthy lifestyle
Pandemic
Internal Medicine
cytokine
Medicine
Humans
awareness
genetics
human
antilipemic agent
Pandemics
risk reduction
Nutrition and Dietetics
familial hypercholesterolemia
business.industry
SARS-CoV-2
pandemic
lipoprotein
Homozygote
help seeking behavior
COVID-19
medicine.disease
anxiety
Virology
cytokine release
medical care
Collateral damage
Blood Component Removal
telemedicine
homozygosity
Cardiology and Cardiovascular Medicine
business
Zdroj: Journal of Clinical Lipidology
Popis: [No abstract available]
Abbott Laboratories; Amgen; Pfizer; Bayer; Sanofi; Actelion Pharmaceuticals; Sanofi Genzyme; Amryt Pharma; Bayer Schering
LC, OKT and SP have no conflicts of interest. MK has received honoraria (for lectures and consultancy) from Abbott, Actelion, Astra-Zeneca, Abdi Ibrahim, Aegerion, Bayer Schering, Menarini, Sanofi Genzyme and Pfizer, and research funding from Aegerion, Amyrt Pharma, Amgen, Pfizer, and Sanofi and has participated in clinical trials with Amgen, Bayer Schering, Sanofi, and for the last 3 years. LT has received honoraria/consultancy fees from Abbott, Actelion, Amgen, Bayer, Daiichi- Sankyo, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati and research funding from Amgen.
Databáze: OpenAIRE
Externí odkaz: